PDF(Pubmed)
Abstract：
Cancer remains the second most common cause of death worldwide affecting around 10 million patients every year. Among the therapeutic options, chemotherapeutic drugs are widely used but often associated with side effects. In addition, toxicity against immune cells may hamper anti-tumor immune responses. Some chemotherapeutic drugs, however, preserve immune functions and some can even stimulate anti-tumor immune responses through the induction of immunogenic cell death (ICD) rather than apoptosis. ICD stimulates the immune system by several mechanisms including the release of damage-associated molecular patterns (DAMPs) from dying cells. In this review, we will discuss the consequences of inducing two recently characterized forms of ICD, i.e., pyroptosis and necroptosis, in the tumor microenvironment (TME) and the perspectives they may offer to increase the immunogenicity of the so-called cold tumors and to stimulate effective anti-tumor immune responses.
摘要：
癌症仍然是全球第二大最常见的死亡原因，每年影响约1000万患者。在治疗选择中，化疗药物被广泛使用，但往往伴随着副作用。此外,对免疫细胞的毒性可能会阻碍抗肿瘤免疫反应。一些化疗药物，然而,维持免疫功能，有些甚至可以通过诱导免疫原性细胞死亡（ICD）而不是凋亡来刺激抗肿瘤免疫反应。ICD通过几种机制刺激免疫系统,包括从死亡细胞释放损伤相关分子模式(DAMPs)。在这次审查中,我们将讨论诱导两种最近表征的ICD形式的后果，即，焦亡和坏死，在肿瘤微环境（TME）中以及它们可能提供的增加所谓的冷肿瘤的免疫原性和刺激有效的抗肿瘤免疫反应的观点。
